Thank everyone our on to call business conference to recently joining results our you, most update. appreciate today's review reported provide us financial We Clint. and
to pleased CTAD study of December data the line were on the in placebo top of syndrome on with disease are continued We treatment the for We and ANAVEX and programs, each overall of lead Xb/X X. across as execution present disease of controlled XXXX double-blind advancement the candidate operations. product Phase X-XX very we excited maintain attention Alzheimer early Rett our business Congress at randomized our our clinical Alzheimer
as secondary of those and measured by co-primary endpoints showing endpoints. both decline reduction met statistically clinical trial significant The
the publication the medical plan to peer data near the We are reviewed data term. and excited for about journal in and submit
growing and healthcare often a to As and in This worldwide. is complex represents burden systems multifactorial, disease societies Alzheimer nature. disease a reminder,
clinical the mechanism that our novel central system nervous of and believe chance We platform success. improve precision medicine
small the of pathway and sigma-X disease is placebo-controlled suggests guided the X-XX results which data the forefront at promoting precision biomarker ANAVEX based by pleased activator homeostasis that be pivotal trial, medicine targeted neural and available might of drug neuroplasticity Alzheimer upstream Phase are cell We molecule Xb/X of orally development. the restoring an to receptor blarcamesine,
urgent We promising data study affected look remains Dementia the forward well by presenting neurodevelopmental of other well long-term a patients of neurodegenerative programs, the complete the therapies, including address the study that believe to other and of as With we Anavex set portfolio positioned needs Rett the in of disease, rare deep Parkinson syndrome. as data to diseases.
the recently Going enrollment Rett study for back X syndrome. February program, placebo-controlled of of the pediatric announced Rett randomized completion patients last EXCELLENCE to Phase the syndrome week, of the with X/X we treatment on
half from results this announce top-line year. in the We expect second to of study this
In Parkinson's recent Phase our and soon, extension we open-label treatment for to planning near trial this of program the to announce indications, the details clinical with of advance it in confirms We Fragile as syndrome. Dementia, initiate share other completed available. from we'll X-XX to XX-week successfully strategy plan the X study. this disease In becomes more are the ANAVEX about FDA X the previously the communication data term
three disease of clinical Foundation, disorders the Fox J. by imaging-focused Anavex applying the neurological clinical study. least, pipeline Phase And platform a X-XX ANAVEX expect burden syndrome and last of illness but we and including treatment X/X Parkinson trial of biomarkers ANAVEX disease for expected, several medicine new X-XX publications Further, planned clinical of initiation is initiation planned an expansion of rare of for X sponsored ANAVEX the study gene clinical of trial initiation response precision our of using the a planned a ANAVEX X-XX Phase Rett not involving indication Michael X-XX and schizophrenia.
for direct financial I Financial to would Sandra the reported Boenisch, Anavex, of Officer now Principal like summary to brief quarter. of a call And the recently
